

48 **Bivalent COVID-19 booster vaccines induce cross-reactive but not BA.5-specific antibodies in**
49 **polyclonal serum**

50
51
52
53
54 Vaccination against the coronavirus disease 2019 (COVID-19) increased immunity in the population
55 reducing viral transmission and protecting against severe disease. However, continuous emergence of
56 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants required the implementation of
57 bivalent boosters including the wild-type (WT, D614G) and BA.5 spike. Improved effectiveness of bivalent
58 vs monovalent booster against Omicron sub-variants was reported [1], however limited differences in the
59 immune response are detected [2, 3].

60
61 We investigated whether a bivalent COVID-19 booster vaccine comprised of WT + BA.5 spike induced
62 detectable BA.5-specific antibody responses in serum. Samples (n=16) collected before [31 days +/- 63 (0
63 – 260)] and after [16 +/- 8 days (6 – 31)] receiving the bivalent booster were tested for antibody binding
64 and avidity to the receptor binding domain (RBD) of WT and BA.5. Neutralization of WT and BA.5 viruses
65 was determined. Omicron-specific antibodies were measured by depletion of WT RBD reactive antibodies
66 and assessment of depleted sera against BA.5 RBD.

67
68 A significant increase in antibody binding to WT and BA.5 RBD and in neutralization of WT and BA.5 viruses
69 were detected following bivalent booster. There were significant differences in binding of post-booster
70 sera between WT and BA.5 RBDs, however differences in neutralization were not significant. Pre- and
71 post- booster RBD antibody avidity was lower against BA.5 vs WT RBD, which prompted us to look for BA.5
72 specific antibodies. WT RBD depleted sera lacked reactivity to WT RBD – as expected – and to BA.5 RBD,
73 suggesting that a single exposure to BA.5 antigens by the administration of bivalent vaccine boosters does
74 not elicit robust levels of BA.5 specific serum antibodies.

75
76 Reduced sensitivity of antibody tests based on WT viral antigens was detected in naïve individuals after
77 Omicron infection [4]. However, most of the population globally has been infected with ancestral strains
78 and/or exposed to WT antigens through vaccination, hence our results are relevant for the current
79 immune status of the population worldwide. Moreover, our data align with recent results indicating that
80 a monovalent booster with BA.1 vaccine elicits robust spike-specific germinal center B cell responses but
81 low levels of *de novo* B cells targeting variant-specific epitopes [5]. Whether further exposures to Omicron
82 antigens will boost these responses to make them detectable in serum remains to be explored.
83 Importantly, it is likely that cross-reactive antibodies towards Omicron-antigens contribute to protection.

84
85 Juan Manuel Carreño, Ph.D.
86 Viviana Simon, MD, Ph.D.
87 Florian Krammer, Ph.D.

88
89 Icahn School of Medicine at Mount Sinai, New York, USA
90 Tel. 212-241-0391
91 Florian.krammer@mssm.edu
92 Viviana.simon@mssm.edu
93 Jm.carreno@mssm.edu

94
95

120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167

Author list

Juan Manuel Carreño*[&]
Gagandeep Singh*
Anass Abbad
Temima Yellin
Komal Srivastava
Charles Gleason
PVI study group
Harm van Bakel
Viviana Simon[&]
Florian Krammer[&]

*Contributed equally

[&]Corresponding authors: Florian Krammer (florian.krammer@mssm.edu), Viviana Simon (viviana.simon@mssm.edu), Juan Manuel Carreño (jm.carreno@mssm.edu)

Supplementary material

Methods

Ethics statement. Sera and data were obtained from two observational studies: the PARIS study (Protection Associated with Rapid Immunity to SARS-CoV-2, approved by the Program for the Protection of Human Subjects at the Icahn School of Medicine at Mount Sinai Institutional Review Board, IRB-20-03374/STUDY-20-00442) and the observational longitudinal clinical sample collection from patients with emerging viral infections research study (approved by the Program for the Protection of Human Subjects at the Icahn School of Medicine at Mount Sinai Institutional Review Board- IRB-17-00791/STUDY-16-01215). Participants from both studies provided informed consent prior to sample and data collection.

Study cohort and serum samples. Blood was collected from individuals before and after receiving a Pfizer (n=10) or Moderna (n=6) bivalent vaccine booster of wild type + BA.5 spike. Samples were collected 31 +/- 63 (0 – 260) days before and 16 +/- 8 (6 – 31) days after bivalent booster vaccination. No comorbidities were reported by the participants. Detailed demographic characteristics and vaccination information per individual and per group are indicated in **Supplementary Tables 1 and 2**.

Cells and viruses. African green monkey Vero.E6 cells expressing transmembrane protease serine 2 (TMPRSS2) were cultured at 37°C with 5% CO₂ in Dulbecco's modified Eagle medium (DMEM, Thermo Fisher Scientific) supplemented with 10% fetal bovine serum (FBS), 1× nonessential amino acids (NEAA), 1% penicillin-streptomycin, 3 µg/ml puromycin (InvivoGen) and 100 µg/ml Normocin (InvivoGen). The SARS-CoV-2 isolate USA-WA1/2020 was used as wild-type reference (BEI Resources, NR-52281) and USA/NY-MSHSPSP-PV58128/2022 provided by the Mount Sinai Pathogen Surveillance Program as representative viral isolate for Omicron BA.5.

Recombinant proteins. Recombinant soluble SARS-CoV-2 proteins were expressed using a mammalian cell protein expression system. SARS-CoV-2 spike, RBD, and NP gene sequences from the ancestral strain

168 Wuhan-1 were cloned into a mammalian expression vector pCAGGs. Proteins were produced in Expi293F
169 cells (Thermo Fisher Scientific) using the ExpiFectamine 293 Transfection Kit (Thermo Fisher Scientific) for
170 plasmid transfection. Spike and RBD cell culture supernatants were harvested at 3 days post-transfection,
171 centrifuged at 4000 x g, and filtered. Proteins were purified using Ni²⁺-nitrilotriacetic acid (Ni-NTA) agarose
172 (Qiagen).. Purified proteins were concentrated using Amicon Ultracell centrifugal units (EMD Millipore),
173 and buffer was exchanged to phosphate buffered saline (PBS, pH 7.4). Protein integrity was assessed using
174 sodium dodecyl sulphate (SDS) polyacrylamide gels (5–20% gradient; Bio-Rad). Proteins stocks were
175 stored at -80°C until used.

176
177 **Binding and avidity measurements.** Antibody binding and avidity levels were assessed using a research-
178 grade enzyme-linked immunosorbent assay (ELISA). Recombinant receptor binding domain (RBD) from
179 the original Wuhan-Hu-1 SARS-CoV-2 isolate (wild-type, WT) and Omicron (BA.5) SARS-CoV-2 were used.
180 Sera was heat inactivated at 56°C for 1h. Ninety-six-well plates (Immulon 4 HBX; Thermo Scientific) were
181 coated with 50 µl/well of recombinant antigen (2 µg/mL) in phosphate-buffered saline (PBS; pH 7.4, Gibco)
182 and incubated overnight at 4°C. Plates were washed 3 times with 1X PBS supplemented with 0.1% Tween-
183 20 (PBS-T; Fisher Scientific) and blocked with 200 µl/well of 3% non-fat milk PBS-T for 1h at room-
184 temperature (RT). Serum dilutions starting at 1:100 followed by 2-fold dilutions were prepared in 1% non-
185 fat milk PBS-T. Blocking solution was removed and dilutions were added to the plates for 2h at RT. Plates
186 were washed 3 times with PBS-T. For avidity measurements, the same sample was incubated with
187 identical sample dilutions in side-by-side columns; one column was treated with 100 µl/well of 8M Urea
188 while the other was left untreated. Plates were incubated for 10 min, then washed as described above.
189 50 µl/well of anti-human IgG (Fab-specific, Sigma-Aldrich, A0293) conjugated to horseradish peroxidase
190 (HRP) prepared in 1% non-fat milk PBS-T at 1:3000 dilutions were added for 1h at RT. Plates were washed
191 3 times and 100 µl/well of o-phenylenediamine dihydrochloride (Sigmafast OPD; Sigma-Aldrich) were
192 added for 10min at RT. To stop the reaction, 50 µl/well of 3 M hydrochloric acid (Thermo Fisher) were
193 added. Optical density (OD) at 490 nm was measured using a Synergy 4 (BioTek) plate reader. Blank wells
194 without serum were used to assess background. Antibody levels expressed as area under the curve (AUC)
195 were calculated by subtracting the background plus three times the standard deviation of the OD. Avidity
196 index (AI) was calculated using the following formula: AI = (Urea-treated sample AUC/Non-treated sample
197 AUC) *100).

198
199 **Antigen coupling to magnetic beads.** Carboxyl magnetic beads (RayBiotech, Peachtree Corners, GA) were
200 coated with RBD from WT SARS-CoV-2 at a ratio of 35 µg of antigen per 100 µl of magnetic beads. Mock
201 beads were prepared using PBS (pH 7.4, Gibco) only instead of antigen. Briefly, 1ml of magnetic beads
202 was transferred to a 1.5ml microtube and washed twice with wash buffer consisting of PBS supplemented
203 with 0.1% BSA and 0.05% Tween-20. Beads were resuspended in 1ml of wash buffer and 350 µg of purified
204 N-terminal 6x his tagged WT RBD antigen were added. The mixture was incubated for 2 h at 4°C with
205 constant shaking. Unbound antigen was removed by passage of beads through a magnetic stand. Coupled
206 beads were quenched by the addition of 1ml (1x volume of beads) of 50 mM Tris, (pH 7.4) and incubation
207 at RT with constant shaking. Quenching buffer was removed using the magnetic stand and conjugated
208 beads were washed 4 times with wash buffer. After the final wash, beads were resuspended in 1ml of
209 wash buffer (1x volume of beads) and stored at 4°C prior to use for antibody depletion.

210
211 **Antibody depletion.** Depletion of antibodies binding to WT RBD was performed using antigen coupled
212 magnetic beads. Sera were diluted in PBS at a 1:10 ratio and 20 µl of antigen coupled magnetic beads or
213 mock beads were added to 100 ul of pre-diluted sera. The mixture was incubated for 2 hours at 4°C with
214 constant shaking. A magnet stand was used to separate the antibody-antigen-bound beads from the 1x

215 depleted sera. 20 μ l of new antigen-coupled beads were added to the 1x depleted sera followed by the
216 same incubation steps as the first round of depletion. 2x depleted sera was used for binding experiments.

217
218 **Microneutralization assay.** Serum samples were screened for neutralizing antibodies against ancestral
219 SARS-CoV-2 USA-WA1/2020 and BA.5. Briefly, 96-well plates were seeded with 2×10^4 Vero.E6 TMPRSS2
220 cells per well in complete Dulbecco's modified Eagle medium (cDMEM) 24 hours before infection. Sera
221 were prediluted 1:10 in infection media consisting of minimal essential media (MEM; Gibco, cat. no.
222 11430-030) supplemented with 2 mM L-glutamine (Gibco, cat. no. 25030081), 0.1% sodium bicarbonate
223 (w/v) (HyClone, cat. no. SH30033.01), 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES;
224 Gibco, cat. no. 15630080), 100 U ml⁻¹ penicillin, 100 μ g ml⁻¹ streptomycin (Gibco, cat. no. 15140122)
225 and 0.2% bovine serum albumin (BSA) (MP Biomedicals, cat. no. 810063). On the second day, serum
226 dilutions were incubated with 10,000 tissue culture infectious dose 50% (TCID₅₀) of virus per ml for one
227 hour at RT. 120 μ l of the virus-serum mix were transferred to every well of Vero.E6 TMPRSS2 plates,
228 followed by incubation for 1h at 37°C. Remdesivir (Medkoo Bioscience inc., cat. no. 329511) was used as
229 a control of virus inhibition at an initial concentration of 10 μ g/ml. Viral inoculum was removed and 100
230 μ l/well of the respective serum dilutions plus 100 μ l/well of infection media supplemented with 2% fetal
231 bovine serum (FBS; Gibco, Ref. 10082-147) were added. Infection was allowed to proceed for 48 hours at
232 37 °C. For nucleoprotein (NP) antigen staining, cell monolayers were fixed with 200 μ l of 10%
233 paraformaldehyde (PFA) overnight at 4 °C. Cells were washed with 1x PBS then permeabilized with 150
234 μ l/well of PBS (pH 7.4) containing 0.1 percent Triton X-100 for 15 minutes at RT. Plates were blocked for
235 1 hour at RT with 200 μ l/well PBS supplemented with 3% BSA. Blocking solution was removed and 100
236 μ l/well of biotinylated monoclonal antibody (mAb) 1C7C7 (mouse anti-SARS NP monoclonal antibody
237 produced at The Icahn School of Medicine at Mount Sinai (ISMMS)) was added at 1 μ g/ml in PBS
238 supplemented with 1% BSA for 1 hour at RT. Cells were washed with 200 μ l/well of PBS twice and
239 100 μ l/well of HRP-conjugated streptavidin (Thermo Fisher Scientific) diluted in PBS supplemented with
240 1% BSA were added at a 1:2,000 dilution for 1 h at room temperature. Plates were washed twice with PBS
241 and 100 μ l/well of Sigmafast OPD were added for 10 minutes at RT. To stop the reaction, 50 μ l/well of a
242 3 M HCl solution (Thermo Fisher Scientific) were added. Optical density (OD, 490 nm) was measured in a
243 Synergy H1 microplate reader (Biotek). For analysis and data representation Prism 9 (GraphPad) was used.
244 Percentage of neutralization, after background subtraction, and compared to the "virus only" control, was
245 calculated. Inhibitory dilution 50% (ID₅₀) was calculated by a non-linear regression curve fit analysis with
246 top and bottom constraints of 100% and 0%, respectively.

247
248 **Statistics.** Differences between groups were assessed using a regular one-way analysis of variance
249 (ANOVA) test with Tukey multiple-comparison. P values lower than 0.0332 were considered statistically
250 significant with a 95% confidence interval. Statistical analyses were performed using Prism 9 (GraphPad,
251 USA).

252 253 **Financial support**

254
255 We thank all the participants of the Personalized Virology Initiative's longitudinal studies for their
256 generous and continued support of research. This effort was supported by the Serological Sciences
257 Network (SeroNet) in part with Federal funds from the National Cancer Institute, National Institutes of
258 Health, under Contract No. 75N91019D00024, Task Order No. 75N91021F00001. The content of this
259 publication does not necessarily reflect the views or policies of the Department of Health and Human
260 Services, nor does mention of trade names, commercial products or organizations imply endorsement by
261 the U.S. Government. This work was also partially funded by the Centers of Excellence for Influenza
262 Research and Surveillance (CEIRS, contract # HHSN272201400008C), the Centers of Excellence for

263 Influenza Research and Response (CEIRR, contract # 75N93021C00014), by the Collaborative Influenza
264 Vaccine Innovation Centers (CIVICs contract # 75N93019C00051) and by institutional funds.

265
266 PVI Study Group: Miriam Fried, Sara Morris, Leeba Sullivan, Hala Alshammary, Dalles Andre, Maria C
267 Bermúdez-González, Gianna Cai, Christian Cognigni, Ana Gonzalez-reiche, Hyun Min Kang, Giulio Kleiner,
268 Neko Lyttle, Jacob Mauldin, Brian Monahan, Jessica Nardulli, Annika Oostenink, Jose Polanco, Ashley
269 Salimbangon, Morgan Van Kesteren.

270

271

272 **Conflict of interest statement**

273

274 The Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2
275 serological assays and NDV-based SARS-CoV-2 vaccines which list Florian Krammer as co-inventor. Dr.
276 Simon is listed on the SARS-CoV-2 serological assays patent. Mount Sinai has spun out a company, Kantaro,
277 to market serological tests for SARS-CoV-2. Dr. Krammer has consulted for Merck and Pfizer (before 2020),
278 and is currently consulting for Pfizer, Seqirus, 3rd Rock Ventures and Avimex and he is a co-founder and
279 scientific advisory board member of CastleVax. The Krammer laboratory is also collaborating with Pfizer
280 on animal models for SARS-CoV-2.

281

282 **Author contributions**

283

284 J.M.C. and F.K. conceptualized study; V.S., C.G., K.S., and the PVI study group enrolled participants,
285 collected data, evaluated surveys, managed IRB approvals, and provided biospecimen and metadata, G.S.,
286 T.Y., and J.M.C. performed experiments; H.v.B. performed sequencing of viral isolates; J.M.C., G.S., and
287 A.A. analyzed data; J.M.C., V.S., and F.K. administered the project; F.K., V.S., and H.v.B. provided
288 resources; J.M.C. and F.K. wrote original draft. All authors reviewed, edited and approved the final version
289 of the manuscript, and have had access to the raw data. Members of the PVI study group collected,
290 processed, stored biospecimen, curated metadata, conducted SARS-CoV-2 precision surveillance and
291 assisted with serological antibody measurements.

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311
312
313
314

Supplementary Table 1. Detailed description of samples used and demographics per individual.

Participant ID ¹	Age Bracket	Sex	Ancestry	Time points included in this study	SARS CoV-2 infection prior to vaccination	Primary Vaccine type	Bivalent booster type
BVB-1	35-39	Male	Caucasian Not Hispanic or Latino	Pre-Boost, Post Boost	No	Pfizer	Moderna
BVB-2	55-59	Male	Caucasian Hispanic or Latino	Pre-Boost, Post Boost	Yes	Moderna	Pfizer
BVB-4	45-49	Male	Caucasian Not Hispanic or Latino	Pre-Boost, Post Boost	Yes	Pfizer	Pfizer
BVB-5	40-44	Female	Other Not Hispanic or Latino	Pre-Boost, Post Boost	Yes	Pfizer	Moderna
BVB-6	45-49	Male	Other Not Hispanic or Latino	Pre-Boost, Post Boost	Yes	Pfizer	Moderna
BVB-7	35-39	Female	Caucasian Not Hispanic or Latino	Pre-Boost, Post Boost	Yes	Pfizer	Pfizer
BVB-8	40-44	Female	Caucasian Not Hispanic or Latino	Pre-Boost, Post Boost	Yes	Pfizer	Pfizer
BVB-9	65-69	Male	Caucasian Not Hispanic or Latino	Pre-Boost, Post Boost	Yes	Pfizer	Pfizer
BVB-10	40-44	Female	Caucasian Not Hispanic or Latino	Pre-Boost, Post Boost	No	Pfizer	Moderna
BVB-11	30-34	Female	Caucasian Not Hispanic or Latino	Pre-Boost, Post Boost	Yes	Pfizer	Pfizer
BVB-12	60-64	Female	Caucasian Not Hispanic or Latino	Pre-Boost, Post Boost	Yes	Pfizer	Pfizer
BVB-13	40-44	Female	Caucasian Not Hispanic or Latino	Pre-Boost, Post Boost	No	Pfizer	Pfizer
BVB-14	70-79	Female	Caucasian Not Hispanic or Latino	Pre-Boost, Post Boost	No	Pfizer	Moderna
BVB-15	40-44	Female	Caucasian Not Hispanic or Latino	Pre-Boost, Post Boost	Yes	Pfizer	Moderna
BVB-16	45-49	Female	Caucasian Not Hispanic or Latino	Pre-Boost, Post Boost	No	Pfizer	Pfizer
BVB-17	70-79	Male	Caucasian Hispanic or Latino	Pre-Boost, Post Boost	Yes	Pfizer	Pfizer

315 Summary of the demographic, infection and vaccination histories of participants from whom serum
316 samples were analyzed. The following abbreviations are used in the table, Pre-Boost: serum collected
317 before the bivalent vaccine booster, Post Boost: serum collected after the bivalent vaccine booster.

318 ¹This is a code (bivalent booster/BVB abbreviation plus random number), not a patient ID.

319
320
321
322
323
324

325
326
327
328

Supplementary Table 2. Age and sex characteristics of individuals per group.

Overall	Number of participants	16
	Average age (min – max)	48 (32 – 73)
	Average days before bivalent booster +/- stdv (min – max)	31 +/- 63 (0 – 260)
	Average days after bivalent booster +/- stdv (min – max)	16 +/- 8 (6 – 31)
Male	Number of participants	6
	Average age (min – max)	53 (37 – 73)
	Average days before bivalent booster +/- stdv (min – max)	13 +/- 17 (0 – 38)
	Average days after bivalent booster +/- stdv (min – max)	17 +/- 8 (10 – 28)
Female	Number of participants	10
	Average age (min – max)	45 (32 – 73)
	Average days before bivalent booster +/- stdv (min – max)	41 +/- 78 (2 – 260)
	Average days after bivalent booster +/- stdv (min – max)	15 +/- 9 (6 – 31)

329 The following abbreviations are used in the table: standard deviation (stdv), minimum (min), maximum
330 (max).

331
332
333
334

References

335
336
337
338
339
340
341
342
343
344
345
346
347

1. Lin, D.Y., et al., *Effectiveness of Bivalent Boosters against Severe Omicron Infection*. N Engl J Med, 2023. **388**(8): p. 764-766.
2. Kurhade, C., et al., *Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster*. Nat Med, 2023. **29**(2): p. 344-347.
3. Wang, Q., et al., *Antibody Response to Omicron BA.4-BA.5 Bivalent Booster*. N Engl J Med, 2023. **388**(6): p. 567-569.
4. Rossler, A., et al., *Reduced sensitivity of antibody tests after omicron infection*. Lancet Microbe, 2023. **4**(1): p. e10-e11.
5. Alsoussi, W.B., et al., *SARS-CoV-2 Omicron boosting induces de novo B cell response in humans*. Nature, 2023.